Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival.
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
received:
31
01
2022
accepted:
05
05
2022
entrez:
17
5
2022
pubmed:
18
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is a common primary liver cancer with poor overall survival. We hypothesized that there are HCC-associated cell-types that impact patient survival. We combined liver single nucleus (snRNA-seq), single cell (scRNA-seq), and bulk RNA-sequencing (RNA-seq) data to search for cell-type differences in HCC. To first identify cell-types in HCC, adjacent non-tumor tissue, and normal liver, we integrated single-cell level data from a healthy liver cohort (n = 9 non-HCC samples) collected in the Strasbourg University Hospital; an HCC cohort (n = 1 non-HCC, n = 14 HCC-tumor, and n = 14 adjacent non-tumor samples) collected in the Singapore General Hospital and National University; and another HCC cohort (n = 3 HCC-tumor and n = 3 adjacent non-tumor samples) collected in the Dumont-UCLA Liver Cancer Center. We then leveraged these single cell level data to decompose the cell-types in liver bulk RNA-seq data from HCC patients' tumor (n = 361) and adjacent non-tumor tissue (n = 49) from the Cancer Genome Atlas (TCGA) multi-center cohort. For replication, we decomposed 221 HCC and 209 adjacent non-tumor liver microarray samples from the Liver Cancer Institute (LCI) cohort collected by the Liver Cancer Institute and Zhongshan Hospital of Fudan University. We discovered a tumor-associated proliferative cell-type, Prol (80.4% tumor cells), enriched for cell cycle and mitosis genes. In the liver bulk tissue from the TCGA cohort, the proportion of the Prol cell-type is significantly increased in HCC and associates with a worse overall survival. Independently from our decomposition analysis, we reciprocally show that Prol nuclei/cells significantly over-express both tumor-elevated and survival-decreasing genes obtained from the bulk tissue. Our replication analysis in the LCI cohort confirmed that an increased estimated proportion of the Prol cell-type in HCC is a significant marker for a shorter overall survival. Finally, we show that somatic mutations in the tumor suppressor genes TP53 and RB1 are linked to an increase of the Prol cell-type in HCC. By integrating liver single cell, single nucleus, and bulk expression data from multiple cohorts we identified a proliferating cell-type (Prol) enriched in HCC tumors, associated with a decreased overall survival, and linked to TP53 and RB1 somatic mutations.
Sections du résumé
BACKGROUND
Hepatocellular carcinoma (HCC) is a common primary liver cancer with poor overall survival. We hypothesized that there are HCC-associated cell-types that impact patient survival.
METHODS
We combined liver single nucleus (snRNA-seq), single cell (scRNA-seq), and bulk RNA-sequencing (RNA-seq) data to search for cell-type differences in HCC. To first identify cell-types in HCC, adjacent non-tumor tissue, and normal liver, we integrated single-cell level data from a healthy liver cohort (n = 9 non-HCC samples) collected in the Strasbourg University Hospital; an HCC cohort (n = 1 non-HCC, n = 14 HCC-tumor, and n = 14 adjacent non-tumor samples) collected in the Singapore General Hospital and National University; and another HCC cohort (n = 3 HCC-tumor and n = 3 adjacent non-tumor samples) collected in the Dumont-UCLA Liver Cancer Center. We then leveraged these single cell level data to decompose the cell-types in liver bulk RNA-seq data from HCC patients' tumor (n = 361) and adjacent non-tumor tissue (n = 49) from the Cancer Genome Atlas (TCGA) multi-center cohort. For replication, we decomposed 221 HCC and 209 adjacent non-tumor liver microarray samples from the Liver Cancer Institute (LCI) cohort collected by the Liver Cancer Institute and Zhongshan Hospital of Fudan University.
RESULTS
We discovered a tumor-associated proliferative cell-type, Prol (80.4% tumor cells), enriched for cell cycle and mitosis genes. In the liver bulk tissue from the TCGA cohort, the proportion of the Prol cell-type is significantly increased in HCC and associates with a worse overall survival. Independently from our decomposition analysis, we reciprocally show that Prol nuclei/cells significantly over-express both tumor-elevated and survival-decreasing genes obtained from the bulk tissue. Our replication analysis in the LCI cohort confirmed that an increased estimated proportion of the Prol cell-type in HCC is a significant marker for a shorter overall survival. Finally, we show that somatic mutations in the tumor suppressor genes TP53 and RB1 are linked to an increase of the Prol cell-type in HCC.
CONCLUSIONS
By integrating liver single cell, single nucleus, and bulk expression data from multiple cohorts we identified a proliferating cell-type (Prol) enriched in HCC tumors, associated with a decreased overall survival, and linked to TP53 and RB1 somatic mutations.
Identifiants
pubmed: 35581624
doi: 10.1186/s13073-022-01055-5
pii: 10.1186/s13073-022-01055-5
pmc: PMC9115949
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : NIH HHS
ID : R01HG010505
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA216807
Pays : United States
Organisme : NIH HHS
ID : U01DK105561
Pays : United States
Organisme : NIH HHS
ID : R01HG006139
Pays : United States
Organisme : NIH HHS
ID : R35GM141798
Pays : United States
Organisme : NIH HHS
ID : R01HG009120
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA246304
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Genet. 2016 May;17(5):257-71
pubmed: 26996076
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Clin Cancer Res. 2015 Jan 1;21(1):175-83
pubmed: 25564571
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nature. 2019 Aug;572(7768):199-204
pubmed: 31292543
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
J Hepatol. 2020 Feb;72(2):215-229
pubmed: 31954487
J Hepatol. 2021 Oct;75(4):865-878
pubmed: 33992698
PLoS Med. 2014 Apr 01;11(4):e1001624
pubmed: 24691105
Science. 2012 Dec 21;338(6114):1622-6
pubmed: 23258894
Cell. 2020 Oct 15;183(2):377-394.e21
pubmed: 32976798
Dig Dis Sci. 2013 Sep;58(9):2713-20
pubmed: 23625295
Hepatology. 2007 Jan;45(1):42-52
pubmed: 17187432
Dig Dis Sci. 2019 Oct;64(10):2878-2892
pubmed: 30949905
Evid Based Complement Alternat Med. 2019 Feb 12;2019:7518374
pubmed: 30891079
Nat Med. 2003 Apr;9(4):416-23
pubmed: 12640447
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Gastroenterology. 2019 Sep;157(3):760-776
pubmed: 31063779
PLoS Genet. 2020 Sep 14;16(9):e1009018
pubmed: 32925908
Nat Med. 2020 May;26(5):792-802
pubmed: 32405060
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Oncol. 2020 Oct 28;10:593383
pubmed: 33194757
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Liver Transpl. 2022 Apr;28(4):725-727
pubmed: 34806834
Genome Biol. 2020 Jun 2;21(1):130
pubmed: 32487174
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Br J Cancer. 1997;76(9):1199-204
pubmed: 9365169
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19802-7
pubmed: 24248345
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Cell Stem Cell. 2019 Jun 6;24(6):927-943.e6
pubmed: 31130514
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Cancer Res. 2018 Feb 15;78(4):853-864
pubmed: 29233929
Cancer Sci. 2020 Feb;111(2):406-417
pubmed: 31785057
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Oncogene. 2017 Jun 22;36(25):3541-3552
pubmed: 28114280
Front Oncol. 2021 Oct 25;11:701736
pubmed: 34760688
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Nat Metab. 2020 Oct;2(10):1113-1125
pubmed: 32989316
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nat Commun. 2020 Apr 24;11(1):1971
pubmed: 32332754
Mol Cell. 2019 Jul 11;75(1):7-12
pubmed: 31299208
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Clin Cancer Res. 2010 Nov 15;16(22):5511-21
pubmed: 20851854
Mol Syst Biol. 2020 Dec;16(12):e9682
pubmed: 33332768
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
PLoS One. 2014 Oct 30;9(10):e110626
pubmed: 25356587
Nat Methods. 2017 Oct;14(10):955-958
pubmed: 28846088
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Science. 2014 Feb 14;343(6172):776-9
pubmed: 24531970
N Engl J Med. 2008 Nov 6;359(19):1995-2004
pubmed: 18923165
Hepatology. 1994 Jul;20(1):15-20
pubmed: 8020885
Hepatol Commun. 2020 Aug 04;4(10):1527-1540
pubmed: 33024921
Nat Commun. 2020 Jan 15;11(1):291
pubmed: 31941899
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Sci Transl Med. 2021 Dec 15;13(624):eabk2267
pubmed: 34910547
Sci Rep. 2020 Jul 3;10(1):11019
pubmed: 32620816
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
World J Gastroenterol. 2010 Nov 14;16(42):5286-96
pubmed: 21072891
Genome Med. 2022 May 17;14(1):50
pubmed: 35581624
Cancer Manag Res. 2019 May 30;11:4947-4956
pubmed: 31239764
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Hepatology. 2021 Jan;73 Suppl 1:14-26
pubmed: 32463918
Hepatobiliary Pancreat Dis Int. 2015 Apr;14(2):171-7
pubmed: 25865690
Exp Ther Med. 2019 Dec;18(6):4893-4903
pubmed: 31772649